Source comparison
Thymosin Alpha-1 for Functional Medicine: Clinical Application Comparison
Chronic Viral Reactivation (EBV, CMV, HHV-6) 1.6–3.2mg twice weekly × 8–12 weeks 4–8 weeks: reduced viral antibody titers, improved fatigue scores EBV VCA IgG, EBV EA IgG, CD4+/CD8+ ratio, NK cell activity Strong evidence for immune rebalancing; most useful wh
This comparison does not assign a generated winner or score.
- Chronic Viral Reactivation (EBV, CMV, HHV-6)
- 1.6–3.2mg twice weekly × 8–12 weeks
- 4–8 weeks: reduced viral antibody titers, improved fatigue scores
- EBV VCA IgG, EBV EA IgG, CD4+/CD8+ ratio, NK cell activity
- Strong evidence for immune rebalancing; most useful when combined with antiviral botanicals
- Long COVID with Persistent Immune Dysregulation
- 1.6mg twice weekly × 12 weeks, then taper
- 6–10 weeks: normalization of CD4+/CD8+ ratio, reduced inflammatory cytokines
- CD4+/CD8+ ratio, IL-6, TNF-α, patient-reported outcome measures (fatigue, brain fog)
- Emerging clinical use; best results in patients with documented T-cell exhaustion markers
- Autoimmune Flare Management (adjunct to standard therapy)
- 1.6mg three times weekly × 4 weeks, then twice weekly × 8 weeks
- 2–6 weeks: reduced autoantibody titers, improved disease activity scores
- CRP, ESR, disease-specific autoantibodies, Treg percentage
- Modulates rather than suppresses immune function; can be used alongside DMARDs
- Cancer Adjuvant (during/after chemotherapy)
- 1.6–3.2mg twice weekly throughout treatment + 12 weeks post
- Immediate (within 1–2 weeks): preserved lymphocyte counts during chemo
- Absolute lymphocyte count, CD4+ count, NK cell activity, post-treatment infection rates
- Strongest clinical evidence base; multiple RCTs show reduced infection risk and improved quality of life
- Immune Senescence in Aging Patients
- 1.6mg once weekly ongoing
- 8–12 weeks: modest improvement in T-cell function markers
- CD4+ naive T-cell percentage, thymic output markers (TREC assay if available)
- Limited high-quality evidence; clinical use based on mechanism rather than robust trials